CellCentric

Alongside the conversion of a loan note from Pfizer made last year to $25m equity, the American Cancer Society’s impact investment and innovation arm, BrightEdge, has also made an additional investment: It all amounts to $60m. The total investment haul will be used to complete clinical testing in alignment with FDA requirements prior to Phase III trials.

CellCentric was co-founded with one of the pioneers of epigenetic research, Professor Azim Surani FRS CBE of the Gurdon Institute, University of Cambridge. Profesor Surani discovered and described an epigenetic code, beyond DNA, that could be inherited and instruct cell fate.